LOS ANGELES, Aug. 14, 2025 /PRNewswire/ --  The DJS Law Group  reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum " or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of SPPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. App ...

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. The lead plaintiff process was reopened by the Court. If you wish to serve as lead plaintiff, you must move the Court no later than Septembe ...

PHILADELPHIA, Aug. 13, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Spectrum (SPPI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Spectrum between March 17, 2022 to September 22, 2022 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholde ...

NEW YORK , Aug. 12, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. The lead plaintiff process was reopened by the Court. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, ...

LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Summit Therapeutics Inc. ("Summit" or "the Company") (NASDAQ: SMMT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 17, 2022 and September 22, 2022, inclusive (the "Class Per ...

诉讼案件 - 波默兰茨律师事务所宣布重新开放针对Spectrum Pharmaceuticals公司投资者的证券集体诉讼首席原告任命程序 [1] - 诉讼涉及Spectrum及其部分高管是否从事证券欺诈或其他非法商业行为 [2] - 投资者需在2025年9月24日前向法院申请成为首席原告 [3] 公司背景 - Spectrum是一家专注于肿瘤治疗的生物制药公司 [3] - 诉讼指控Spectrum就其Pinnacle研究(涉及肺癌治疗药物poziotinib的临床试验)向投资者作出虚假或误导性陈述 [3] 律所信息 - 波默兰茨律师事务所在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处 [4] - 该律所在公司、证券和反垄断集体诉讼领域享有盛誉 [4] - 律所已为集体诉讼成员追回多笔数百万美元的损害赔偿 [4]

诉讼案件 - 波默朗茨律师事务所宣布重新开放针对Spectrum Pharmaceuticals投资者的证券集体诉讼首席原告任命程序 [1] - 诉讼涉及Spectrum及其部分高管是否从事证券欺诈或其他非法商业行为 [2] - 投资者需在2025年9月24日前向法院申请成为首席原告 [2] 公司背景 - Spectrum是一家专注于肿瘤治疗的生物制药公司 [4] - 诉讼指控Spectrum就其Pinnacle研究向投资者作出虚假或误导性陈述 [4] - 争议涉及poziotinib药物的临床试验 该药物用于治疗特定肺癌患者 [4] 律师事务所 - 波默朗茨律师事务所在公司 证券和反垄断集体诉讼领域处于领先地位 [5] - 该事务所已为集体诉讼成员追回多笔数百万美元的损害赔偿 [5]

公司调查 - 律师事务所Berger Montague PC正在调查Spectrum Pharmaceuticals Inc (NASDAQ: SPPI)涉嫌证券欺诈的指控 代表在2022年3月17日至2022年9月22日期间购买或获得该公司普通股的投资者 [1] - 投资者需在2025年9月24日前申请成为集体诉讼的首席原告代表 [2] - Spectrum是一家专注于肿瘤治疗的生物制药公司 [2] 诉讼指控 - 集体诉讼指控Spectrum就其Pinnacle Study(一项涉及治疗特定肺癌患者的药物poziotinib的临床试验)向投资者作出虚假或误导性陈述 [3] - Spectrum股票在与Assertio Holdings Inc (NASDAQ: ASRT)合并后被摘牌 [3] 律师事务所信息 - Berger Montague成立于1970年 在证券集体诉讼领域具有开创性地位 代表个人和机构投资者超过50年 在美国各地法院担任首席律师 [5] - 事务所在费城 明尼阿波利斯 特拉华 华盛顿特区 圣地亚哥 旧金山 芝加哥 宾夕法尼亚州马尔文和多伦多设有办事处 [5]

公司动态 - 律师事务所Berger Montague PC正在调查Spectrum Pharmaceuticals Inc (NASDAQ: SPPI)涉嫌证券欺诈的案件 代表在2022年3月17日至2022年9月22日期间购买或获得Spectrum普通股的投资者 [1] - Spectrum是一家专注于肿瘤治疗的生物制药公司 [2] - 集体诉讼指控Spectrum就其Pinnacle Study(涉及治疗特定肺癌患者的药物poziotinib的临床试验)向投资者作出虚假或误导性陈述 [3] - Spectrum股票在公司与Assertio Holdings Inc (NASDAQ: ASRT)合并后被摘牌 [3] 投资者行动 - 在集体诉讼期间购买或获得Spectrum证券的投资者可在2025年9月24日前寻求被任命为集体诉讼的首席原告代表 [2] - 投资者可通过指定联系方式了解更多信息或讨论其权利 [4][6] 律师事务所背景 - Berger Montague PC成立于1970年 是证券集体诉讼领域的先驱 在费城 明尼阿波利斯 特拉华 华盛顿特区 圣地亚哥 旧金山 芝加哥 宾夕法尼亚州马尔文和多伦多设有办事处 [5] - 该律所代表个人和机构投资者已超过50年 并担任美国各地法院的首席法律顾问 [5]